Ribavirin (Virazole) — CPB 0155 | AETNA Coverage Update

Aetna modified CPB 0155 covering ribavirin (Virazole) inhalation therapy, effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated its ribavirin coverage policy under CPB 0155 in the Aetna Clinical Policy Bulletins system. This policy governs inhaled ribavirin (Virazole) for serious viral infections including RSV in high-risk patients and viral hemorrhagic fevers. The update affects claims coded with B97.4, A98.0, B33.4, and related ICD-10 diagnosis codes. If your team bills for ribavirin inhalation therapy — particularly in pediatric, oncology, or infectious disease settings — this change affects your claims.

Quick-Reference Table

Aetna Ribavirin (Virazole) Coverage Criteria and Medical Necessity Requirements 2025

Aetna's ribavirin coverage policy under CPB 0155 is narrow and specific. Aetna considers ribavirin inhalation medically necessary for three categories of patients only.

The first is RSV infection in immunosuppressed and high-risk children and adults. This is the most common clinical scenario your billing team will encounter. Think bone marrow transplant patients, children with congenital heart disease, or adults on immunosuppressive therapy. RSV in these patients codes to B97.4, and that code needs to be front and center on your claim.

The second covered indication is viral hemorrhagic fever — specifically Crimean-Congo (A98.0), Ebola, Lassa, and Marburg. These are rare in US clinical settings, but if your facility treats international travelers or manages bioterrorism preparedness protocols, these cases do appear. Marburg and related conditions map to A96.2 and A98.3–A98.4 ranges in the ICD-10 data.

The third indication is Rift Valley fever and Hantaan (a hantavirus). Rift Valley fever maps to the A92.x code range. Hantavirus pulmonary syndrome maps to B33.4. These are geographically concentrated cases, but they do occur in the US Southwest and in travelers returning from endemic regions.

Medical necessity hinges on matching the right diagnosis to the right indication. A ribavirin inhalation claim for a patient without documented immunosuppression, hemorrhagic fever, or hantavirus infection will not meet Aetna's medical necessity criteria. Document the underlying condition thoroughly in the medical record before the claim goes out.

The CPB 0155 Aetna system also references CPT 90378 — RSV monoclonal antibody for intramuscular use, 50 mg each — as a related code. This is listed under "other CPT codes related to the CPB," not as a covered ribavirin billing code. Don't conflate the two. CPT 90378 is a separate product (nirsevimab/palivizumab territory), not ribavirin.

Prior authorization requirements are not explicitly stated in the updated CPB 0155 text, but Aetna routinely requires prior auth for specialty inhalation drugs in institutional settings. Check your specific plan contract and confirm prior authorization requirements with Aetna directly before the September 26, 2025 effective date if you're unsure.

Coverage Indications at a Glance

Aetna Ribavirin Inhalation Billing Guidelines and Action Items 2025

These steps apply to any facility or practice billing ribavirin inhalation therapy to Aetna-covered patients. Execute these before September 26, 2025.

1. Audit your active ribavirin inhalation orders for ICD-10 alignment.
Pull every open order for inhaled Virazole in your system. Confirm each maps to one of the three covered indications: RSV in an immunosuppressed or high-risk patient, viral hemorrhagic fever, or Rift Valley fever / hantavirus. Claims without a supporting covered diagnosis will generate a claim denial.

2. Verify immunosuppression documentation for every RSV case.
RSV coded to B97.4 is not automatically covered. Aetna's medical necessity standard requires the patient to be immunosuppressed or otherwise high-risk. Your documentation needs to spell that out — not just code B97.4 and hope it passes. Include the underlying condition (e.g., myeloid leukemia — C92.x range, malignant neoplasm codes, transplant status) as a secondary diagnosis on the claim.

3. Confirm your dosing documentation matches the SPAG-2 protocol.
The policy references a specific dosing regimen: 20 mg/mL Virazole in the SPAG-2 unit, administered continuously for 12–18 hours per day for three to seven days. Average aerosol concentration is 190 mcg/L of air over a 12-hour delivery period. If your administration records don't reflect this protocol, your clinical and billing documentation are misaligned — and that's a reimbursement risk on audit.

4. Don't bill CPT 90378 as a ribavirin billing substitute.
CPT 90378 (RSV monoclonal antibody, IM, 50 mg each) is listed in the CPB as a related code — not a covered code for ribavirin inhalation. These are different drugs, different routes, different indications. Mixing them up in your charge capture creates a claim denial that's hard to fix after the fact.

5. Check prior authorization requirements for your specific Aetna plan contracts.
CPB 0155 doesn't spell out prior auth requirements in its current text, but Aetna's prior authorization requirements for specialty inhalation therapy vary by plan. Contact your Aetna provider relations rep or check the Aetna provider portal before September 26, 2025. If you bill a significant volume of ribavirin inhalation claims, loop in your compliance officer to confirm your PA workflow is current.

6. Flag oncology and transplant patients as a separate audit population.
The ICD-10 code list attached to CPB 0155 includes a wide range of malignant neoplasm and myeloid leukemia codes (C92.x range, C00.0–C10.9, C72.x, C73). These are the underlying conditions that establish high-risk or immunosuppressed status for RSV coverage. Your billing team should cross-reference the primary diagnosis against these supporting codes to build a defensible claim.

CPT, HCPCS, and ICD-10 Codes for Ribavirin (Virazole) Under CPB 0155

Key ICD-10-CM Diagnosis Codes

These are the diagnosis codes listed in CPB 0155. Use these to support medical necessity on ribavirin inhalation claims.

Viral Infections (Primary Covered Indications)

Rift Valley Fever and Mosquito-Borne Fever Codes

Underlying Conditions Supporting Immunosuppressed / High-Risk Status for RSV

These codes establish the high-risk or immunosuppressed status required for RSV coverage under CPB 0155. Bill these as secondary diagnoses alongside B97.4.

A Note on the ICD-10 Code Scope

The 148-code ICD-10 list attached to CPB 0155 is worth a moment of your attention. It includes neoplasm codes (glioblastoma, thyroid cancer, oral cavity malignancies, myeloid leukemia) alongside infectious disease codes. These oncology codes aren't covered indications for ribavirin on their own. They're listed because they establish the immunosuppressed or high-risk patient status that makes RSV infection eligible for ribavirin coverage.

This is a common pattern in Aetna policy coding structures — the diagnosis code list reflects both the primary indication and the underlying conditions that satisfy the medical necessity standard. Your billing guidelines should reflect that distinction. Train your coding team: B97.4 plus a supporting cancer or immunosuppressive diagnosis code builds the medical necessity case. B97.4 alone may not.

The policy's citation of a 2019 Virazole drug label as the dosing source is worth flagging for your medical director and compliance officer. Drug labeling from 2019 may not reflect current clinical practice. If your facility's ribavirin protocols have evolved since then, document how your practice aligns with — or why it departs from — the labeled regimen. That documentation protects you on audit.